Clinical trials: Anti-CD20 Therapy
Graves´ Disease, Thyroid Associated Ophthalmopathy
Rituximab in the Treatment of Graves' Disease
Aim: In a phase II pilot study encompassing 20 patients with Graves' disease to evaluate the effect of rituximab: 1. Biochemically as assessed by markers of disease activity ( free T4, free T3, TSH, TSH-receptor antibodies…
- Trial name
- NCT00150111
- Testing
- Methimazole, Rituximab, Immunization with various vaccines
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Odense University Hospital
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
- Trial name
- NCT05094206
- Testing
- 0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Medical College of Wisconsin
Rheumatoid Arthritis
Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy
The purpose of this study is to examine the effect of anti-TNF therapy on rheumatoid arthritis using magnetic resonance imaging (MRI) and ultrasound imaging.
- Trial name
- NCT01083563
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Immune Thrombocytopenia (ITP), Autoantibodies
TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
This prospective, open-label, nonrandomized, multicenter clinical trial aims at comparing the efficacy and safety of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody vs.
- Conditions
- Immune Thrombocytopenia (ITP), Autoantibodies, Evan Syndrome, Connective Tissue Diseases
- Trial name
- NCT04915482
- Testing
- Combined use of TPO-RAs with low-dose anti-CD20 antibody, The best available therapy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
Background: About 23,000 people die from B-cell cancers in the US each year. These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells.
- Conditions
- Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell
- Trial name
- NCT05797233
- Testing
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
- Trial name
- HERMOSA-2 (NCT07304154)
- Testing
- KITE-363, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 57 people
- Sponsor
- Kite, A Gilead Company
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.
- Trial name
- SCRIPT (NCT00476996)
- Testing
- Leflunomide, Methotrexate, Ocrelizumab
- Where
- 266 sites in United States, Argentina and 23 more
- Volunteers
- 836 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims…
- Trial name
- NCT07566988
- Where
- United States
- Volunteers
- 2,604 people
- Sponsor
- Novartis Pharmaceuticals
Leukaemia, Lymphocytic, Chronic
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment.
- Trial name
- PROLONG (NCT01039376)
- Testing
- Ofatumumab, Observation
- Where
- 203 sites in United States, Argentina and 23 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
This study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
- Trial name
- NCT07038447
- Testing
- KITE-363, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 52 people
- Sponsor
- Kite, A Gilead Company
Mantle Cell Lymphoma
Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)
Mantle Cell Lymphoma (MCL) is a malignancy with a poor response to treatment and with a median survival of 2- 4 years since diagnosis.
- Trial name
- LCM-04-02 (NCT00505232)
- Testing
- Y-90 Ibritumomab tiuxetan
- Where
- 16 sites in Spain
- Volunteers
- 30 people
- Sponsor
- CABYC
B-cell Non-Hodgkin Lymphoma (B-NHL)
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells…
- Trial name
- ELM-2 (NCT03888105)
- Testing
- Odronextamab
- Where
- 119 sites in United States, Australia and 12 more
- Volunteers
- 515 people
- Sponsor
- Regeneron Pharmaceuticals
Rheumatoid Arthritis
Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, pain, stiffness, damage, and ultimately loss of joint function.
- Trial name
- NCT00396812
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)
An open-label, multicenter study to evaluate the safety and immunogenicity of inactivated VZV vaccine (V212) in participants with hematologic malignancies (HM) who are currently receiving anti-CD20 monoclonal antibodies.
- Trial name
- NCT01460719
- Testing
- V212
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Central Nervous System Lymphoma
Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma.
- Trial name
- NCT00293475
- Testing
- Carboplatin, Mannitol, Methotrexate
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Sclerosis
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered…
- Trial name
- OSSIA (NCT07609719)
- Testing
- OCR SC
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Relapsed/Refractory Large B-Cell Lymphoma
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the…
- Trial name
- ELEVATION (NCT05800977)
- Testing
- Prizloncabtagene autoleucel
- Where
- 15 sites in China
- Volunteers
- 112 people
- Sponsor
- Shanghai AbelZeta Ltd.
Moderately to Severely Active Rheumatoid Arthritis
Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis
To compare the efficacy between the HLX01 group and the placebo group through the proportion of subjects meeting the ACR20 improvement criteria for remission
- Trial name
- NCT03522415
- Testing
- HLX01, Methotrexate（MTX）
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Shanghai Henlius Biotech
Marginal Zone Lymphoma(MZL)
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
In patients with previously untreated Marginal zone lymphoma (MZL), a treatment regimen of Orelabrutinib,Zuberitamab combined with Cyclophosphamide,Vincristine,Prednisoneacetatetablets is planned to be used.
- Trial name
- NCT07480863
- Testing
- Orelabrutinib, Zuberitamab, Cyclophosphamide
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rheumatoid Arthritis
An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab
This multicenter prospective observational study will evaluate the quality of life in participants with rheumatoid arthritis (RA) who are initiated with rituximab (MabThera/Rituxan).
- Trial name
- NCT02507752
- Where
- 20 sites in Brazil
- Volunteers
- 94 people
- Sponsor
- Hoffmann-La Roche